rabeprazole + colloidal pectin bismuth + metronidazole + clarithromycin

This drug is a fixed-dose combination therapy consisting of four active ingredients: rabeprazole (a proton pump inhibitor), colloidal pectin bismuth (a gastroprotective agent with antimicrobial properties), metronidazole (an antibiotic effective against anaerobic bacteria and protozoa), and clarithromycin (a macrolide antibiotic). The combination is designed for the eradication of Helicobacter pylori infection, which is associated with peptic ulcer disease and gastric cancer. Rabeprazole reduces gastric acid secretion, creating a less acidic environment that enhances the effectiveness of antibiotics. Colloidal pectin bismuth provides mucosal protection and has direct antibacterial activity against H. pylori. Metronidazole disrupts DNA synthesis in susceptible organisms, while clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This quadruple regimen targets H. pylori through multiple mechanisms to overcome resistance patterns seen with dual or triple therapies.